Long-Term Indomethacin Treatment in a Chinese Child with Gitelman Syndrome: Case Report and Literature Review on its Efficacy and Tolerance
- PMID: 38069462
- PMCID: PMC10720922
- DOI: 10.12659/AJCR.941627
Long-Term Indomethacin Treatment in a Chinese Child with Gitelman Syndrome: Case Report and Literature Review on its Efficacy and Tolerance
Abstract
BACKGROUND Gitelman syndrome (GS) is a rare inherited autosomal recessive salt-losing renal tubulopathy. Early-onset GS is difficult to differentiate from Bartter syndrome (BS). It has been reported in some cases that cyclooxygenase (COX) inhibitors, which pharmacologically reduce prostaglandin E2(PGE2) synthesis, are helpful for GS patients, especially in children, but the long-term therapeutic effect has not yet been revealed. CASE REPORT A 4-year-old boy was first brought to our hospital for the chief concern of short stature and growth retardation. Biochemical tests demonstrated severe hypokalemia, hyponatremia, and hypochloremic metabolic alkalosis. The patient's serum magnesium was normal. He was diagnosed with BS and treated with potassium supplementation and indomethacin and achieved stable serum potassium levels and slow catch-up growth. At 11.8 years of age, the patient showed hypomagnesemia and a genetic test confirmed that he had GS with compound heterozygous mutations in the SLC12A3 gene. At the age of 14.8 years, when indomethacin had been taken for nearly 10 years, the boy reported having chronic stomachache, while his renal function remained normal. After proton pump inhibitor and acid inhibitor therapy, the patient's symptoms were ameliorated, and he continued to take a low dose of indomethacin (37.5 mg/d divided tid) with good tolerance. CONCLUSIONS Early-onset GS in childhood can be initially misdiagnosed as BS, and gene detection can confirm the final diagnosis. COX inhibitors, such as indomethacin, might be tolerated by pediatric patients, and long-term therapy can improve the hypokalemia and growth retardation without significant adverse effects.
Conflict of interest statement
Figures
Similar articles
-
Early onset children's Gitelman syndrome with severe hypokalaemia: a case report.BMC Pediatr. 2020 Aug 5;20(1):366. doi: 10.1186/s12887-020-02265-9. BMC Pediatr. 2020. PMID: 32758191 Free PMC article.
-
Inherited salt-losing tubulopathy: An old condition but a new category of tubulopathy.Pediatr Int. 2020 Apr;62(4):428-437. doi: 10.1111/ped.14089. Epub 2020 Apr 13. Pediatr Int. 2020. PMID: 31830341 Review.
-
A novel compound heterozygous variant of the SLC12A3 gene in Gitelman syndrome with diabetes and the choices of the appropriate hypoglycemic drugs: a case report.BMC Med Genomics. 2021 Aug 4;14(1):198. doi: 10.1186/s12920-021-01047-1. BMC Med Genomics. 2021. PMID: 34348722 Free PMC article.
-
Mutations in SLC12A3 and CLCNKB and Their Correlation with Clinical Phenotype in Patients with Gitelman and Gitelman-like Syndrome.J Korean Med Sci. 2016 Jan;31(1):47-54. doi: 10.3346/jkms.2016.31.1.47. Epub 2015 Dec 24. J Korean Med Sci. 2016. PMID: 26770037 Free PMC article.
-
Gitelman syndrome combined with diabetes mellitus: A case report and literature review.Medicine (Baltimore). 2023 Dec 15;102(50):e36663. doi: 10.1097/MD.0000000000036663. Medicine (Baltimore). 2023. PMID: 38115360 Free PMC article. Review.
Cited by
-
Concurrent Gitelman Syndrome and Hyperthyroidism: Diagnostic Challenges in a 51-Year-Old Patient.Am J Case Rep. 2024 Aug 30;25:e944909. doi: 10.12659/AJCR.944909. Am J Case Rep. 2024. PMID: 39210578 Free PMC article.
References
-
- Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: Consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24–33. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources